(Total Views: 329)
Posted On: 08/08/2018 2:11:05 PM
Post# of 72447
Here's how ridiculous this valuation is. ARTH has a slightly higher market cap than IPIX, at 65.719 million.
ARTH has ONE possible product, a new (and way better) surgical glue.
ONE product. Not very far in clinical trials -- FDA asked them for more patients in their Phase 1.
IPIX? Well, I need not rehash about 3 drugs with multiple applications, and nothing but successful clinical trials.
But I do not think that ARTH is overvalued. It's just that IPIX is so grossly undervalued.
ARTH has ONE possible product, a new (and way better) surgical glue.
ONE product. Not very far in clinical trials -- FDA asked them for more patients in their Phase 1.
IPIX? Well, I need not rehash about 3 drugs with multiple applications, and nothing but successful clinical trials.
But I do not think that ARTH is overvalued. It's just that IPIX is so grossly undervalued.
(8)
(0)
